NeoGenomics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance.
NeoGenomics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance.
neogenomics股票在公司發佈高於預期的2024財年營業收入和利潤的第二季度業績後上漲。
NeoGenomics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance.
neogenomics股票在公司發佈高於預期的2024財年營業收入和利潤的第二季度業績後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。